Cell Therapeutics vor Tounaround?
Agenda
On February 10, 2010, during the morning session, the committee will discuss new drug application (NDA) 022-481, proposed trade name PIXUVRI (pixantrone dimaleate) injection, manufactured by Cell Therapeutics, Inc. The proposed indication (use) for this product is as a single agent treatment for patients with recurring or refractory (difficult to treat), aggressive non-Hodgkin’s lymphoma (NHL) who have received two or more prior lines of therapy.
Link: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm195221.htm
Cell Therapeutics, Inc. (NASDAQ: CTIC) will present at the JP Morgan 28th Annual Healthcare Conference. The company is scheduled to give their presentation on January 14th at 2:00pm (PST).The conference is taking place in San Francisco at the Westin St. Francis Hotel. The presentation will be made available via webcast through the company's website.
TryPennyStocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer.
Sign up for the free TryPennyStocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About TryPennyStocks
TryPennyStocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that could be on the brink of a breakout. To feature a company on our web site please contact us at the email listed below.
du haltest ja auch anx
also meiner meinung hast du den ja schon!
:)))
lg
Morgen kaufe ich mich noch in einer anderen Firma ein und dann ist erstmal genug :)
http://www.google.com/finance?q=US1509345039
jm